Literature DB >> 7828613

Assessment of cerebral perfusion with single-photon emission tomography in normal subjects and in patients with Alzheimer's disease: effects of region of interest selection.

J J Claus1, F van Harskamp, M M Breteler, E P Krenning, T J van der Cammen, A Hofman, D Hasan.   

Abstract

The shape, size and location of regions of interest (ROIs) show considerable variability between single-photon emission tomography (SPET) studies in aging and Alzheimer's disease, but the possible influence on study results remains unknown. We compared three different ROIs in a SPET study with 60 controls and in 48 patients with probable Alzheimer's disease diagnosed according to the NINCDS-ADRDA criteria. Regional cerebral blood flow (rCBF) was assessed with SPET using technetium-99m d,l-hexamethylpropylene amine oxime (99mTc-HMPAO), normalized to the mean activity in a cerebellar reference slice. The three different ROIs were: a multi-slice and a single-slice ROI with reference to the normal brain anatomy (using an anatomical atlas), and a rectangular (2 x 4 pixels) ROI in the frontal, temporal, temporoparietal and occipital cortices. No differences were observed for the means of rCBF values between the single-slice and multi-slice ROI's with reference to the normal anatomy, but some variability was present for individual comparisons. In contrast, significantly higher mean rCBF values were obtained with the single-slice rectangular ROIs in all four regions for both patients and controls and considerable variability was shown for individual subjects. After analysis with multivariate logistic regression and receiver operator characteristic curves, the ability of SPET to discriminate between controls and Alzheimer patients was similar in the three methods for mild and moderate Alzheimer patients (Global Deterioration Scale = GDS of 3 and 4). However, with increasing dementia severity (GDS > 4) the rectangular ROIs showed lower ability to discriminate between groups compared to the single-slice and multi-slice anatomically defined ROIs.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7828613     DOI: 10.1007/bf00181058

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  31 in total

1.  A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia.

Authors:  M O Habert; U Spampinato; J L Mas; M L Piketty; M C Bourdel; J de Recondo; P Rondot; S Askienazy
Journal:  Eur J Nucl Med       Date:  1991

2.  Correlation between regional cerebral blood flow and oxidative metabolism. In vivo studies in man.

Authors:  M E Raichle; R L Grubb; M H Gado; J O Eichling; M M Ter-Pogossian
Journal:  Arch Neurol       Date:  1976-08

3.  Selection and interpretation of diagnostic tests and procedures. Principles and applications.

Authors:  P F Griner; R J Mayewski; A I Mushlin; P Greenland
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

4.  Blood flow metabolism couple in brain.

Authors:  M Reivich
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1974

5.  99mTc-d,l-HMPAO and SPECT of the brain in normal aging.

Authors:  G Waldemar; S G Hasselbalch; A R Andersen; F Delecluse; P Petersen; A Johnsen; O B Paulson
Journal:  J Cereb Blood Flow Metab       Date:  1991-05       Impact factor: 6.200

6.  Regional cerebral blood flow imaging: a quantitative comparison of technetium-99m-HMPAO SPECT with C15O2 PET.

Authors:  H G Gemmell; N T Evans; J A Besson; D Roeda; J Davidson; M G Dodd; P F Sharp; F W Smith; J R Crawford; R H Newton
Journal:  J Nucl Med       Date:  1990-10       Impact factor: 10.057

7.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

8.  A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease.

Authors:  J T O'Brien; S Eagger; G M Syed; B J Sahakian; R Levy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

9.  Differential diagnosis in dementia using the cerebral blood flow agent 99mTc HM-PAO: a SPECT study.

Authors:  H G Gemmell; P F Sharp; J A Besson; J R Crawford; K P Ebmeier; J Davidson; F W Smith
Journal:  J Comput Assist Tomogr       Date:  1987 May-Jun       Impact factor: 1.826

10.  Measurements of regional cerebral blood flow and cognitive performance in Alzheimer's disease.

Authors:  D Montaldi; D N Brooks; J H McColl; D Wyper; J Patterson; E Barron; J McCulloch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-01       Impact factor: 10.154

View more
  5 in total

1.  Functional neuroimaging in Alzheimer's disease: how far should we go?

Authors:  R Kerwin
Journal:  Eur J Nucl Med       Date:  1994-10

2.  Variability of cerebral blood flow deficits in 99mTc-HMPAO SPECT in patients with Alzheimer's disease.

Authors:  R Zimmer; S Leucht; T Rädler; F Schmauss; U Gebhardt; H Lauter
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Vascular risk factors, atherosclerosis, cerebral white matter lesions and cerebral perfusion in a population-based study.

Authors:  J J Claus; M M Breteler; D Hasan; E P Krenning; M L Bots; D E Grobbee; J C van Swieten; F van Harskamp; A Hofman
Journal:  Eur J Nucl Med       Date:  1996-06

Review 4.  The Legacy of the TTASAAN Report-Premature Conclusions and Forgotten Promises: A Review of Policy and Practice Part I.

Authors:  Dan G Pavel; Theodore A Henderson; Simon DeBruin
Journal:  Front Neurol       Date:  2022-03-28       Impact factor: 4.086

5.  Diagnosis of regional cerebral blood flow abnormalities using spect: agreement between individualized statistical parametric maps and visual inspection by nuclear medicine physicians with different levels of expertise in nuclear neurology.

Authors:  Euclides Timóteo da Rocha; Carlos Alberto Buchpiguel; Ricardo Nitrini; Sergio Tazima; Stela Verzinhase Peres; Geraldo Busatto Filho
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.